Previous 10 | Next 10 |
2024-05-10 07:31:44 ET More on IN8bio IN8bio gains after new preclinical data for nsCAR-T cell therapy platform Seeking Alpha’s Quant Rating on IN8bio Historical earnings data for IN8bio Financial information for IN8bio Read the full article ...
- Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue - Demonstrated potential of nsCAR platform to treat previously “undruggable” soli...
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, announced today that the first patient in its Phase 2 clinical trial evaluating INB-400 in patients with newly diagnosed...
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking p...
2024-04-11 08:16:21 ET More on pre-market losers stock Grifols: Q4 Was Positive, Still Too Many Question Marks Altice USA: Recent Refinancing Buys Time But Challenges Remain Altice USA, Inc. (ATUS) Q4 2023 Earnings Call Transcript Altice slips as Wells Fargo ...
2024-04-10 09:49:14 ET More on IN8bio Seeking Alpha’s Quant Rating on IN8bio Historical earnings data for IN8bio Financial information for IN8bio Read the full article on Seeking Alpha For further details see: IN8bio gains after new preclin...
2024-04-10 07:17:31 ET DENVER, Colo., Apr 10, 2024 ( 247marketnews.com )- IN8bio, Inc. (NASDAQ: INAB ) reported, after yesterday’s market close, new preclinical data from INB-300, its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell platform, which demo...
- Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue - Gamma-delta nsCAR platform emerging as an advanced technology for targeting hematologic and solid tumor cancers NEW YORK, April 09, 2024 (GLOB...
2024-03-14 17:54:40 ET More on IN8bio In8bio stock jumps 11% following clinical update Seeking Alpha’s Quant Rating on IN8bio Historical earnings data for IN8bio Financial information for IN8bio Read the full article on Seeking Alpha Fo...
Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100 in Leukemia where 100% of Evaluable Patients (n=10) Treated Remained in Remission, including six Patients Alive and Progression Free Past 12 Months Presented Positive Results ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will participate in a fireside chat during the H.C. Wainwrigh...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 1.8% to $131.88 on volume of 307,014,213 shares SRIVARU Holding Limited (SVMH) rose 49.2% to $0.2275 on volume of 274,465,266 shares Nauticus Robotics Inc. (KITT) rose 19.6% to $0.192 on volume of 161,46...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...